ARHGEF16

Across TCGA pan-cancer cohorts, ARHGEF16 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARHGEF16 data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher ARHGEF16 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ARHGEF16 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LGG, UCEC, and ACC are the cancer types where ARHGEF16 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.221	0.889	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.682	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARHGEF16–LGG (OS)

Open the LGG breakdown →